Business
Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), to commercialize CXG87 in Mainland China. Under the terms of the agreement, Chance Pharma, as the MAH (Marketing Author
About this update from Huadong Medicine Co., Ltd. Class A
[{"type":"text","content":"HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), to commercialize CXG87 in Mainland China. Under the terms of the agreement, Chance Pharma, as the MAH (Marketing Authorization Holder), will be responsible for the research and development, registration, manufacturing, and supply of the CXG87. Chance will receive an upfront fee, regulatory and commercial milestone payments, and a share of sales profits. Huadong Medicine will be responsible for the commercialization and marketing of CXG87 in mainland China.","length":917,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Chance Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Chance Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":70,"url":"https://media.zenfs.com/en/prnewswire.com/89589b32c5267c452c40adcac817611d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NLjob920F4gQY.rYoUcaXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/89589b32c5267c452c40adcac817611d","width":400,"height":70}},"href":"https://mma.prnewswire.com/media/2071613/Chance_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CXG87 is an improved therapy of budesonide/formoterol powder. It is a Class 2.2 new drug independently developed by Chance Pharma for the treatment of respiratory diseases such as asthma. Currently, the Phase III clinical trial for the asthma indication has completed enrollment of all subjects, and the new drug application is expected to be submitted in the first half of 2026.","length":379,"tagName":"p"},{"type":"text","content":"Mr. Liang Lv, Chairman and General Manager of Huadong Medicine, commented: "We see significant potential for CXG87 in respiratory treatment. This partnership will strategically enhance our respiratory pipeline and, by leveraging our nationwide commercial network and specialized promotion team, w...